{"version":"1.0","provider_name":"Market Newsdesk","provider_url":"https:\/\/www.marketnewsdesk.com","author_name":"Newsdesk","author_url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/","title":"Cardax Reports Q3 2020 Results - Market Newsdesk","type":"rich","width":600,"height":338,"html":"<blockquote class=\"wp-embedded-content\" data-secret=\"dIpaD1JrzL\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/cardax-reports-q3-2020-results\/\">Cardax Reports Q3 2020 Results<\/a><\/blockquote><iframe sandbox=\"allow-scripts\" security=\"restricted\" src=\"https:\/\/www.marketnewsdesk.com\/index.php\/cardax-reports-q3-2020-results\/embed\/#?secret=dIpaD1JrzL\" width=\"600\" height=\"338\" title=\"&#8220;Cardax Reports Q3 2020 Results&#8221; &#8212; Market Newsdesk\" data-secret=\"dIpaD1JrzL\" frameborder=\"0\" marginwidth=\"0\" marginheight=\"0\" scrolling=\"no\" class=\"wp-embedded-content\"><\/iframe><script>\n\/*! This file is auto-generated *\/\n!function(d,l){\"use strict\";l.querySelector&&d.addEventListener&&\"undefined\"!=typeof URL&&(d.wp=d.wp||{},d.wp.receiveEmbedMessage||(d.wp.receiveEmbedMessage=function(e){var t=e.data;if((t||t.secret||t.message||t.value)&&!\/[^a-zA-Z0-9]\/.test(t.secret)){for(var s,r,n,a=l.querySelectorAll('iframe[data-secret=\"'+t.secret+'\"]'),o=l.querySelectorAll('blockquote[data-secret=\"'+t.secret+'\"]'),c=new RegExp(\"^https?:$\",\"i\"),i=0;i<o.length;i++)o[i].style.display=\"none\";for(i=0;i<a.length;i++)s=a[i],e.source===s.contentWindow&&(s.removeAttribute(\"style\"),\"height\"===t.message?(1e3<(r=parseInt(t.value,10))?r=1e3:~~r<200&&(r=200),s.height=r):\"link\"===t.message&&(r=new URL(s.getAttribute(\"src\")),n=new URL(t.value),c.test(n.protocol))&&n.host===r.host&&l.activeElement===s&&(d.top.location.href=t.value))}},d.addEventListener(\"message\",d.wp.receiveEmbedMessage,!1),l.addEventListener(\"DOMContentLoaded\",function(){for(var e,t,s=l.querySelectorAll(\"iframe.wp-embedded-content\"),r=0;r<s.length;r++)(t=(e=s[r]).getAttribute(\"data-secret\"))||(t=Math.random().toString(36).substring(2,12),e.src+=\"#?secret=\"+t,e.setAttribute(\"data-secret\",t)),e.contentWindow.postMessage({message:\"ready\",secret:t},\"*\")},!1)))}(window,document);\n\/\/# sourceURL=https:\/\/www.marketnewsdesk.com\/wp-includes\/js\/wp-embed.min.js\n<\/script>\n","description":"&#8211; Operating loss decreased vs. Q3 2019 &#8211; Net loss decreased vs. Q3 2019 &#8211; ZanthoSyn\u00ae revenues decreased vs. Q3 2019 &#8211; Cardax invited to submit updated federal grant application for COVID-19 clinical trial PR Newswire HONOLULU, Nov. 13, 2020 \/PRNewswire\/ &#8212; Cardax, Inc. (OTCQB:CDXI) reported its Q3 2020 results. Highlights: Financial Results . Operating loss decreased from $1,191,711 in Q3 2019 to $705,760 in Q3 2020, primarily due to a decrease in professional fees, research &amp; development, salaries &amp; wages, and selling, general, &amp; administrative expenses. Net loss for the same three-month period decreased from $1,433,626 to $1,354,331 for the same reasons. Operating loss decreased from $3,355,386 in the nine-months ended September 30, 2019, to $2,400,823 in the same &hellip; Continue reading \"\"","thumbnail_url":"https:\/\/mma.prnewswire.com\/media\/549255\/Cardax_Logo.jpg"}